drugset / Trial / NCT07511205

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

NCT07511205 ↗

Phase 1 Recruiting 104 enrolled AstraZeneca Parexel · collab
RandomizedSequentialTriple-blindTreatment

Summary

The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent.

Timeline

Start
2026-03-30
Primary completion
2027-04-09
Completion
2027-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1043 Unknown — Subcutaneous

Indications